Table 1.

Summary of HOXB13 G84E Mutations in Prostate-Cancer Case Subjects and Control Subjects of European Descent.*

Data Set	G84E Carriers	G84E Noncarriers	Carrier Frequency	Comparison with 1401 Control Subjects †		Comparison with Expanded Pool of Control Subjects ‡
				Odds Ratio	P Value	Odds Ratio	P Value
	no.		%
UM-PCGP and Johns Hopkins University
All subjects§	72	5011	1.4	20.1	8.5×10−7	9.5	2.4×10−9
Subjects from 85 sequenced families with  hereditary prostate cancer	4	81	4.7	68.4	4.8×10−5	32.6	5.4×10−5
UM-PCGP
Subjects with early-onset or hereditary  prostate cancer§	26	1104	2.3	33.0	1.0×10−8	15.6	1.3×10−10
Johns Hopkins University
Subjects with hereditary prostate cancer§ and  those undergoing prostatectomy or other  oncologic therapy	46	3907	1.2	16.5	1.6×10−5	7.8	6.0×10−7
Control subjects
Johns Hopkins University	1	1400	0.1	NA	NA	NA	NA
Exome Sequencing Project plus CEU HapMap	3	1258	0.2	NA	NA	NA	NA

^*The HOXB13 G84E mutation was detected by means of both direct sequencing and high-throughput genotyping approaches. CEU denotes Centre d’Etude du Polymorphisme Humain from Utah, NA not applicable, and UM-PCGP University of Michigan Prostate Cancer Genetics Project.

^†Case subjects were compared with 1401 control subjects at Johns Hopkins University.

^‡Case subjects were compared with 1401 control subjects at Johns Hopkins University plus 1233 subjects in the Exome Sequencing Project and 28 unrelated genotyped subjects from the CEU HapMap.

^§This category includes unrelated subjects with prostate cancer, excluding the 85 families of European descent used for discovery. The youngest available subject with prostate cancer was selected from families that had more than one subject with the disease.